Mentor Capital's Investment in Quantum Immunologics Offers Potential Broad Application in Cancer Treatment

Strategic Insights -

Mentor Capital, Inc. has made a strategic investment in Quantum Immunologics, a company developing an immunotherapy that has received FDA authorization for a Phase I/II human clinical study in advanced-stage metastatic breast cancer. This immunotherapy, which utilizes dendritic cell therapy, has the potential to be applied to multiple cancer lines, offering a more cost-effective approach for investors. Furthermore, the partnership between Quantum Immunologics and Auburn University aims to extend the cancer-fighting immunotherapy to the veterinary market, highlighting the broad applicability of the technology.

Key Takeaways:

  • Mentor Capital, Inc. has invested in Quantum Immunologics, a company developing an immunotherapy for cancer treatment.
  • The immunotherapy has received FDA authorization for a Phase I/II human clinical study in advanced-stage metastatic breast cancer.
  • The study involves 27 patients and is designed to test the proprietary dendritic cell therapy.
  • The partnership between Quantum Immunologics and Auburn University will extend the immunotherapy to the veterinary market through a jointly-owned and independently-funded company.
  • The company aims to leverage the University's expertise in animal oncology and license Quantum's proprietary oncofetal antigen-based therapy as the underlying technology.
  • Mentor Capital's public market value should closely track the major investment it holds in Quantum Immunologics.
  • The implied valuation of 100% of Quantum Immunologics is $7 million at the current Mentor share price of $1.50.
  • Mentor Capital is working to significantly increase its investment in Quantum Immunologics to add value for existing and new shareholders.

Statistics:

  • 27 patients are involved in the Phase I/II human clinical study of Quantum Immunologics' immunotherapy.
  • The company has received FDA authorization for the study.
  • The partnership between Quantum Immunologics and Auburn University will begin its operation in mid-2010.
  • The proposed valuation of 100% of Quantum Immunologics is $7 million.
  • The current price of Mentor Capital shares is $1.50.

Sources:

  • Mentor Capital, Inc. (Pink Sheets:MNTR)
  • Quantum Immunologics
  • NewsRx.com
  • Cancer Weekly